Trial · NCT07089719
Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study)
NCT07089719, Phase 2, Not yet recruiting, Assistance Publique - Hôpitaux de Paris
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study). Trials, record NCT07089719. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07089719
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study)
- NCT number
- NCT07089719
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 21 participants, estimated
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Conditions
- Dyspnea Caused by 2019-nCoV
- Interventions
- Bevacizumab Injection
- First posted
- 2025-07-28
- Last updated
- 2025-07-28
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of patients with 10% increase of impaired DLCO | 3 months after the introduction of bevacizumab. | Assess efficacy of bevacizumab injection in long COVID patients with impaired DLCO (\<75% of predicted value). The positive criteria will be a 10% increase in DLCO at three months after the introduction of bevacizumab. |
| Secondary | Proportion of patients with recovery of clinical symptoms | 1, 2, 3 and 7 months after the initiation of Bevacizumab. | Modification of clinical evaluation and in particular the clinical symptom of dyspnea and fatigue or other related clinical parameters of long-COVID patients (mMRC Scale, Borg Scale, STOP-BANG Questionnaire, WHODAS 2.0, Epworth Sleepiness Scale, which assess fatigue severity in long-COVID patients). |
| Secondary | Proportion of patients with recovery of psychological, cognitive, and autonomic functions | 3 and 7 months after the initiation of Bevacizumab treatment. | Evaluation of psychological, cognitive, and autonomic functions. In particular, additional assessments will be conducted to evaluate psychological, cognitive, and autonomic functions with the Nijmegen Questionnaire, the Hospital Anxiety and Depression Scale, the Montreal Cognitive Assessment, the self-reported Ricci-Gagnon Physical Activity Questionnaire, the Somatic Symptom Disorder Scale-12 (SSD-12) and the Survey of Autonomic Symptoms. |
| Secondary | Proportion of patients with improvement of other parameter than DLCO explored by Pulmonary Function Test | 1, 2, 3 and 7-months after the initiation of Bevacizumab treatment. | Modification of other respiratory function markers: forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio, total lung capacity (TLC), residual volume (RV), and 6-minutes walking distance test between baseline and follow-up. |
| Secondary | Modification of DLCO | 1 and 2 months after the initiation of Bevacizumab treatment. | Difference of DLCO between baseline and follow-up. |
| Secondary | Circulating angiogenic biomarkers levels | 1, 2, 3 and 7 months after the initiation of Bevacizumab treatment. | Difference of circulating angiogenic biomarkers levels between baseline and follow-up. |
| Secondary | Number of side effects related to bevacizumab | From bevacizumab treatment initiation to the end of the follow-up at 7 months. | Safety of bevacizumab in long-COVID patients regarding treatment side effects. |
| Secondary | Number of patients with hospitalization or medical consultation | From bevacizumab treatment initiation to the end of the follow-up at 7 months. | Safety of bevacizumab in long-COVID patients regarding hospitalization or medical consultation. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 37526809 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07089719
GET https://conductscience.org/api/trials/v1/NCT07089719/registered